One-Time gene infusion aims to fight duchenne muscular dystrophy
NCT ID NCT07673809
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests a single intravenous dose of a gene therapy called GNR-097 in boys aged 4 to 9 with Duchenne muscular dystrophy (DMD). The therapy uses a harmless virus to deliver a shortened version of the dystrophin gene, which is missing or faulty in DMD. The trial aims to see if the treatment is safe and whether it can improve muscle function. Some participants will receive a placebo first and may get the gene therapy later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GNR-097 (a gene therapy using a harmless virus to deliver a shortened dystrophin gene)
- What this could lead to
- If successful, this could provide a one-time treatment that helps boys with Duchenne muscular dystrophy maintain muscle strength and slow disease progression.
- What could go wrong
- This is an early-phase trial with only 32 participants, so results may not apply to everyone. There are risks of serious side effects like muscle inflammation, heart inflammation, or blood clotting issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Medical Research Center for Children
RECRUITINGMoscow, 119991, Russia
-
Regional Children's Clinical Hospital
RECRUITINGYekaterinburg, 620149, Russia
-
Republican Scientific and Practical Center Mother and Child
RECRUITINGMinsk, 220053, Belarus
-
Russian Children's Clinical Hospital
RECRUITINGMoscow, 117513, Russia
-
Saint Petersburg State Pediatric Medical University
RECRUITINGSaint Petersburg, 194100, Russia
-
Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University
RECRUITINGMoscow, 125412, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lower steroid dose preserve strength in young boys with DMD?
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- Can a massive patient database unlock new treatments for muscular dystrophy?
- Umbilical cord stem cells aim to slow muscle loss in duchenne boys
- Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
- Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy